Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
出版年份 2019 全文链接
标题
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Cancers
Volume 11, Issue 11, Pages 1798
出版商
MDPI AG
发表日期
2019-11-16
DOI
10.3390/cancers11111798
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma
- (2019) Erik Yusko et al. Cancer Immunology Research
- Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
- (2019) Christopher J. D. Wallis et al. JAMA Oncology
- Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
- (2019) Biagio Ricciuti et al. Journal for ImmunoTherapy of Cancer
- Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer
- (2019) Young Kwang Chae et al. ONCOLOGIST
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
- (2019) C Luchini et al. ANNALS OF ONCOLOGY
- Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer
- (2019) Wenfeng Fang et al. CLINICAL CANCER RESEARCH
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab
- (2019) Omid Hamid et al. CLINICAL CANCER RESEARCH
- Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer
- (2019) Han Chang et al. Molecular Diagnosis & Therapy
- High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
- (2019) Dedong Cao et al. OncoImmunology
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibiotic therapy and outcome from immune-checkpoint inhibitors
- (2019) David J. Pinato et al. Journal for ImmunoTherapy of Cancer
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer
- (2018) Roelof J. Beukinga et al. RADIOLOGY
- Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
- (2018) Genevieve P Hartley et al. Cancer Immunology Research
- Association of tumor mutational burden with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer
- (2018) Young Kwang Chae et al. Clinical Lung Cancer
- Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis
- (2018) Ivo Buchhalter et al. INTERNATIONAL JOURNAL OF CANCER
- Sex as a predictor of response to cancer immunotherapy
- (2018) Cristina Carrera et al. LANCET ONCOLOGY
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- (2018) Diana Miao et al. NATURE GENETICS
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
- (2018) Xian Shen et al. BMJ-British Medical Journal
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
- (2018) Jake R. Conway et al. Genome Medicine
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
- (2017) Robert Brody et al. LUNG CANCER
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters
- (2017) Tian-Tian Zhai et al. RADIOTHERAPY AND ONCOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
- (2017) Jingshu Wang et al. Journal of Managed Care & Specialty Pharmacy
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
- (2016) Jason Roszik et al. BMC Medicine
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Biomarker-Based Scoring System for Prediction of Tumor Response After Preoperative Chemoradiotherapy in Rectal Cancer by Reverse Transcriptase Polymerase Chain Reaction Analysis
- (2016) Hyuk Hur et al. DISEASES OF THE COLON & RECTUM
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
- (2016) Tavi Nathanson et al. Cancer Immunology Research
- PD-L1 Testing in Cancer
- (2016) Aaron R. Hansen et al. JAMA Oncology
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Gender Disparity and Mutation Burden in Metastatic Melanoma
- (2015) Sameer Gupta et al. JNCI-Journal of the National Cancer Institute
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Gender Disparity and Mutation Burden in Metastatic Melanoma
- (2015) Sameer Gupta et al. JNCI-Journal of the National Cancer Institute
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started